Award

Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease

Description: Given the global ageing population, Alzheimer's disease (AD) numbers are expected to triple in the next 40 years. However, there remains a lack of effective treatment options for this disease. Current interventions are limited to drug therapy with little to modest benefits on patients' symptoms. Thus, in response to this problem and the rising number of affected individuals, research has been geared towards identifying factors that can be targeted to prevent AD onset. Recently, mounting evidence has pointed towards the potential role of Helicobacter pylori (H.pylori) infection in the development of AD. Using a large database from the United Kingdom, we will reassess this question by looking more specifically at manifesting infection. To do so, we will be comparing patients with and without clinically apparent H.pylori infection and their risk of developing AD. Findings from this study will provide critical knowledge on the role of clinically manifesting H.pylori in AD, which could inform the development of novel AD treatment or prevention strategies.
Amount: CA$160,700
Funding type: research
Funder scheme: Project Grant
Start date: 2022-10-01
End date: 2024-09-30
Investigator: Paul Brassard (lead)
Institutions: Lady Davis Institute for Medical Research, Lady Davis Institute for Medical Research (Mtl)
Field: Medicine
Funded outputs count: 0
Funder award ID: 183856_1
OpenAlex ID: G1538894264